Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced NSCLC: Longer Follow-Up of the MARIPOSA Study : Episode 3

Safety Considerations for Frontline Amivantamab Plus Lazertinib

October 15, 2024

By Joshua K. Sabari, MD
Sandip Patel, MD

Opinion

Video

Panelists discuss how they implement prophylactic strategies for treatment-related adverse events in the MARIPOSA study and how they counsel patients about managing these effects.

EP: 1.Overview of MARIPOSA Study

EP: 2.Amivantamab Plus Lazertinib Clinical Efficacy

Now Viewing

EP: 3.Safety Considerations for Frontline Amivantamab Plus Lazertinib

EP: 4.Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

EP: 5.Putting Amivantamab Plus Lazertinib Into Practice

EP: 6.Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!